Cited 0 times in
OA10.05: An Open-Label, Multicenter, Phase II Single Arm Trial of Osimertinib in NSCLC Patients with Uncommon EGFR Mutation(KCSG-LU15-09)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.